Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer-Reference-Cited by-同舟云学术

Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer

Published:2012-08-28 Issue:9 Volume:11 Page:4605-4614
ISSN:1535-3893
Container-title:Journal of Proteome Research
language:en
Short-container-title:J. Proteome Res.

Author:

Chappell Nicole P.¹²,Teng Pang-ning²,Hood Brian L.²,Wang Guisong²,Darcy Kathleen M.²,Hamilton Chad A.¹²,Maxwell G. Larry²³,Conrads Thomas P.²

Affiliation:

1. Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, Maryland, United States

2. Women’s Health Integrated Research Center at Inova Health System, Gynecologic Cancer Center of Excellence, Annandale, Virginia, United States

3. Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Fairfax, Virginia, United States

Publisher

American Chemical Society (ACS)

Subject

General Chemistry,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/pr300403d

Reference52 articles.

1. Cancer statistics, 2012

2. Cisplatin: mode of cytotoxic action and molecular basis of resistance

3. How do real tumors become resistant to cisplatin?

4. Recent progress in the diagnosis and treatment of ovarian cancer

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MUL1 identified as mitochondria-linked biomarker promoting cisplatin resistance in OC cells;Gene;2024-12

2. A proteomic landscape of pharmacologic perturbations for functional relevance;Journal of Pharmaceutical Analysis;2024-01

3. Metastasis suppressor genes in clinical practice: are they druggable?;Cancer and Metastasis Reviews;2023-09-25

4. Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective;Molecular & Cellular Proteomics;2023-07

5. From Basics of Coordination Chemistry to Understanding Cisplatin-analogue Pt Drugs;Current Pharmaceutical Design;2023-06